I believe GILD is an attractive long-term investment due to its strong Q4 2024 results and promising 2025 guidance, coupled with its high dividend yie...
Read
More
I believe GILD is an attractive long-term investment due to its strong Q4 2024 results and promising 2025 guidance, coupled with its high dividend yield and positive outlook in the HIV and oncology segments. These factors position Gilead as a solid choice amidst growing investor interest.
With the promising results from Gilead's HIV drug lenacapavir and the anticipated growth in the anti-retroviral drugs market, I believe GILD presents ...
Read
More
With the promising results from Gilead's HIV drug lenacapavir and the anticipated growth in the anti-retroviral drugs market, I believe GILD presents a strong long-term investment opportunity. Its undervalued status and reliable dividend further solidify my confidence in its potential for substantial upside ahead.
With the recent announcement of a twice-daily medication for HIV prevention that shows 96% efficacy, I see a strong potential upside for GILD. This br...
Read
More
With the recent announcement of a twice-daily medication for HIV prevention that shows 96% efficacy, I see a strong potential upside for GILD. This breakthrough could drive significant interest and capital towards the stock in the coming weeks.
Primary Biliary congitis received FDA accelerated approval this week. Ensuring cashflow of $4billionnfor current affected patients and all future pati...
Read
More
Primary Biliary congitis received FDA accelerated approval this week. Ensuring cashflow of $4billionnfor current affected patients and all future patients by being the only valuable treatment for this disease. Not to mention $Gild has obesity drugs in the pipeline as well to catch up with the rest. Plus this giant has been accumulating for 5+years